Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Oct 17

PMID 36245985

Authors

Yiheng Jiang

Shengbo Huang

Xinqing Zhu

Liang Cheng

Wenlong Liu

Qiwei Chen

Deyong Yang

Affiliations

Soon will be listed here.

Abstract

Background: To construct and validate a deep learning cluster from whole slide images (WSI) for depicting the immunophenotypes and functional heterogeneity of the tumor microenvironment (TME) in patients with bladder cancer (BLCA) and to explore an artificial intelligence (AI) score to explore the underlying biological pathways in the developed WSI cluster.

Methods: In this study, the WSI cluster was constructed based on a deep learning procedure. Further rerecognition of TME features in pathological images was applied based on a neural network. Then, we integrated the TCGA cohort and several external testing cohorts to explore and validate this novel WSI cluster and a corresponding quantitative indicator, the AI score. Finally, correlations between the AI cluster (AI score) and classical BLCA molecular subtypes, immunophenotypes, functional heterogeneity, and potential therapeutic method in BLCA were assessed.

Results: The WSI cluster was identified associated with clinical survival ( < 0.001) and was proved as an independent predictor ( = 0.031), which could also predict the immunology and the clinical significance of BLCA. Rerecognition of pathological images established a robust 3-year survival prediction model (with an average classification accuracy of 86%, AUC of 0.95) for BLCA patients combining TME features and clinical features. In addition, an AI score was constructed to quantify the underlying logic of the WSI cluster (AUC = 0.838). Finally, we hypothesized that high AI score shapes an immune-hot TME in BLCA. Thus, treatment options including immune checkpoint blockade (ICB), chemotherapy, and ERBB therapy can be used for the treatment of BLCA patients in WSI cluster1 (high AI score subtype).

Conclusions: In general, we showed that deep learning can predict prognosis and may aid in the precision medicine for BLCA directly from H&E histology, which is more economical and efficient.

Citing Articles

Machine learning approaches for spatial omics data analysis in digital pathology: tools and applications in genitourinary oncology.

Kim H, Kim J, Yeon S, You S Front Oncol. 2024; 14:1465098.

PMID: 39678498 PMC: 11638011. DOI: 10.3389/fonc.2024.1465098.

Efficient diagnosis of IDH-mutant gliomas: 1p/19qNET assesses 1p/19q codeletion status using weakly-supervised learning.

Kim G, Lee T, Ahn S, Uh Y, Kim S NPJ Precis Oncol. 2023; 7(1):94.

PMID: 37717080 PMC: 10505231. DOI: 10.1038/s41698-023-00450-4.

Recent Advancements in Deep Learning Using Whole Slide Imaging for Cancer Prognosis.

Lee M Bioengineering (Basel). 2023; 10(8).

PMID: 37627783 PMC: 10451210. DOI: 10.3390/bioengineering10080897.

Molecular classification of urothelial bladder carcinoma.

Schwarzova L, Novakova Z, Danisovic L, Ziaran S Mol Biol Rep. 2023; 50(9):7867-7877.

PMID: 37525073 PMC: 10460735. DOI: 10.1007/s11033-023-08689-7.

References

Courtiol P, Maussion C, Moarii M, Pronier E, Pilcer S, Sefta M . Deep learning-based classification of mesothelioma improves prediction of patient outcome. Nat Med. 2019; 25(10):1519-1525. DOI: 10.1038/s41591-019-0583-3. View

Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B . Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Front Immunol. 2020; 11:1956. PMC: 7477085. DOI: 10.3389/fimmu.2020.01956. View

LeCun Y, Bengio Y, Hinton G . Deep learning. Nature. 2015; 521(7553):436-44. DOI: 10.1038/nature14539. View

Jiang Y, Yang M, Wang S, Li X, Sun Y . Emerging role of deep learning-based artificial intelligence in tumor pathology. Cancer Commun (Lond). 2020; 40(4):154-166. PMC: 7170661. DOI: 10.1002/cac2.12012. View

Choi W, Porten S, Kim S, Willis D, Plimack E, Hoffman-Censits J . Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014; 25(2):152-65. PMC: 4011497. DOI: 10.1016/j.ccr.2014.01.009. View

Aleksakhina S, Imyanitov E . Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. Int J Mol Sci. 2021; 22(20). PMC: 8536080. DOI: 10.3390/ijms222010931. View

Garcia-Mulero S, Alonso M, Pardo J, Santos C, Sanjuan X, Salazar R . Lung metastases share common immune features regardless of primary tumor origin. J Immunother Cancer. 2020; 8(1). PMC: 7319789. DOI: 10.1136/jitc-2019-000491. View

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J . Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018; 362(6411). PMC: 6718162. DOI: 10.1126/science.aar3593. View

Woerl A, Eckstein M, Geiger J, Wagner D, Daher T, Stenzel P . Deep Learning Predicts Molecular Subtype of Muscle-invasive Bladder Cancer from Conventional Histopathological Slides. Eur Urol. 2020; 78(2):256-264. DOI: 10.1016/j.eururo.2020.04.023. View

10.

Chen D, Mellman I . Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013; 39(1):1-10. DOI: 10.1016/j.immuni.2013.07.012. View

11.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

12.

Coudray N, Ocampo P, Sakellaropoulos T, Narula N, Snuderl M, Fenyo D . Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning. Nat Med. 2018; 24(10):1559-1567. PMC: 9847512. DOI: 10.1038/s41591-018-0177-5. View

13.

Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I . Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018; 6(1):63. PMC: 6013904. DOI: 10.1186/s40425-018-0367-1. View

14.

Shah J, McConkey D, Dinney C . New strategies in muscle-invasive bladder cancer: on the road to personalized medicine. Clin Cancer Res. 2011; 17(9):2608-12. DOI: 10.1158/1078-0432.CCR-10-2770. View

15.

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

16.

Botteman M, Pashos C, Redaelli A, Laskin B, Hauser R . The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 2004; 21(18):1315-30. DOI: 10.1007/BF03262330. View

17.

Ott P, Bang Y, Piha-Paul S, Abdul Razak A, Bennouna J, Soria J . T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. J Clin Oncol. 2018; 37(4):318-327. DOI: 10.1200/JCO.2018.78.2276. View

18.

Hu J, Othmane B, Yu A, Li H, Cai Z, Chen X . 5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer. BMC Med. 2021; 19(1):289. PMC: 8627095. DOI: 10.1186/s12916-021-02163-6. View

19.

Wang H, Zhong J, Wu C, Liu Y, Zhang J, Zou X . Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells. Oncol Rep. 2017; 38(2):917-925. DOI: 10.3892/or.2017.5711. View

20.

Guo G, Sun X, Chen C, Wu S, Huang P, Li Z . Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013; 45(12):1459-63. PMC: 7512009. DOI: 10.1038/ng.2798. View